Liquidia Resubmits New Drug Application for LIQ861 (treprostinil) Inhalation Powder for the Treatment of Pulmonary Arterial Hypertension MORRISVILLE, N.C., May 10, 2021 (GLOBE NEWSWIRE) — Liquidia Corporation (NASDAQ: LQDA)
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.Ok
